ArriVent BioPharma
AVBP · Nasdaq · United States
Share price · AVBP
Loading chart…
Prices are end-of-day (EOD), delayed by 24 hours · Adjusted for stock splits · Data via Databento
Unusual price moves
Days when AVBP's shares moved far more than they usually do, with what was announced that day or the session before. An announcement on the same day does not show that it caused the move. How the days are picked
- 26 Oct 2026-26.9%
- 6 Oct 2026-47.0%
- 25 Aug 2026+10.9%
Nothing announced by AVBP that day or the session before.
- 22 Jul 2026+7.7%
Nothing announced by AVBP that day or the session before.
- 20 Jul 2026-15.0%
Nothing announced by AVBP that day or the session before.
- 24 Jun 2026-5.1%
Nothing announced by AVBP that day or the session before.
- 4 Jun 2026+11.1%
Nothing announced by AVBP that day or the session before.
- 29 May 2026+12.2%
Nothing announced by AVBP that day or the session before.
- 20 Apr 2026+5.9%
Nothing announced by AVBP that day or the session before.
- 9 Apr 2026+7.9%
Nothing announced by AVBP that day or the session before.
Share of unusual movement by asset
For each asset, the share of AVBP's own-move activity since 3 Nov 2025 that fell on the session of one of the asset's own announcements or the session after it. Large moves count for much more than small ones. A session shared by several assets is split between them. A share is shown once an asset has at least 8 event days; below that, its events are listed instead.
| Asset | Event days | Share of unusual movement |
|---|---|---|
Furmonertinibevents and moves
| 3 | shown from 8 days |
| Assets with fewer than 8 event days, together | — | 38% |
| Other company news (earnings, financing, releases naming no asset) | — | 16% |
| Sessions with no dated event | — | 46% |
Assets
(1 total)
| Target & Modality | |||
|---|---|---|---|
| Phase 3 | EGFRSmall molecule | Non-Small Cell Lung Cancer |
Upcoming events
(5 total)
Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.
2026 (1)
December 2026 (1)
What to watch
2027 (1)
December 2027 (1)
What to watch
2028 (1)
October 2028 (1)
What to watch
2029 (2)
February 2029 (1)
What to watch
March 2029 (1)
What to watch
Regulatory and conference events
(1)
Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.
Recent
Financial reports
Quarterly & interim (12)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2026-Q3 | $5.0M | $39M | $114M+ $280M short-term inv. | $40M-$41M operating cash flow | report ↗ |
View 11 more
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2026-Q2 | — | $42M | $155M+ $218M short-term inv. | $50M-$40M operating cash flow | report ↗ |
| 2026-Q1 | — | $38M | $62M+ $264M short-term inv. | $43M-$42M operating cash flow | report ↗ |
| 2025-Q3 | — | $32M | $113M+ $188M short-term inv. | $35M-$36M operating cash flow | report ↗ |
| 2025-Q2 | — | $28M | $113M+ $123M short-term inv. | $31M-$26M operating cash flow | report ↗ |
| 2025-Q1 | — | $61M | $50M+ $126M short-term inv. | $64M-$68M operating cash flow | report ↗ |
| 2024-Q3 | — | $20M | $283M | $21M-$16M operating cash flow | report ↗ |
| 2024-Q2 | — | $22M | $299M | $22M-$19M operating cash flow | report ↗ |
| 2024-Q1 | — | $17M | $317M | $17M-$19M operating cash flow | report ↗ |
| 2023-Q3 | — | $14M | $141M | $14M-$15M operating cash flow | report ↗ |
| 2023-Q2 | — | $20M | $158M | $22M-$8.6M operating cash flow | report ↗ |
| 2023-Q1 | — | $10M | $191M | $12M-$17M operating cash flow | report ↗ |
Annual history (4 years)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2025-FY | — | $153M | $46M+ $267M short-term inv. | $42M-$161M operating cash flow | report ↗ |
Insider transactions
Open-market activity, trailing 12 months: 0 purchases ($0), 1 sale ($13.0M). Awards, option exercises and tax-withholding rows are listed below but excluded from these totals.
| Source | ||||||
|---|---|---|---|---|---|---|
| 2026-10-30 | LaChapelle Robin · Chief Operating Officer | Option exercise | 16,265 | $3.65 | $59K | Form 4 |
| 2026-10-30 | LaChapelle Robin · Chief Operating Officer | Option exercise | 410 | $2.28 | $935 | Form 4 |
| 2026-10-30 | LaChapelle Robin · Chief Operating Officer | Option exercise | 4,550 | $2.28 | $10K | Form 4 |
| 2026-10-30 | LaChapelle Robin · Chief Operating Officer | Option exercise | 1,820 | $2.28 | $4K | Form 4 |
| 2026-10-30 | LaChapelle Robin · Chief Operating Officer | Option exercise | 17,648 | $6.24 | $110K | Form 4 |
| 2026-10-30 | LaChapelle Robin · Chief Operating Officer | Option exercise (derivative) | 410 | — | — | Form 4 |
| 2026-10-30 | LaChapelle Robin · Chief Operating Officer | Option exercise (derivative) | 4,550 | — | — | Form 4 |
| 2026-10-30 | LaChapelle Robin · Chief Operating Officer | Option exercise (derivative) | 1,820 | — | — | Form 4 |